Mankind Pharma Ltd.

₹2,226.4

19.2 (0.9%)

MANKIND Share Price

Pharmaceuticals & Biotechnology

As on March 5, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 91,556 Cr

P/E Ratio46.14

Dividend YieldN/A

Trendline Performance

We are partnered with TradingView to provide dynamic charts and powerful tools for market analysis.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	2,241.28	Bearish
10-DMA	2,152.72	Bullish
20-DMA	2,113.55	Bullish
50-DMA	2,145.87	Bullish
100-DMA	2,216.7	Bullish
200-DMA	2,353.57	Bearish

Historical Performance

1 Year

-2.7%

3 Years

N/A

5 Years

N/A

10 Years

N/A

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	1,22,074	1,02,604	87,494	77,816	62,144
Total Expenditure	91,870	77,453	68,475	57,910	45,653
Other Income	5,368	2,802	1,286	1,960	1,709
Operating Profit	35,573	27,954	20,305	21,866	18,201
Interest	4,320	342	458	598	212
Depreciation	6,212	3,784	3,259	1,666	1,190
Profit Before Tax	25,163	23,979	16,712	19,746	16,916
Consolidated Net Profit	19,910	19,129	12,819	14,335	12,654
Adjusted EPS	48	48	32	36	32

Compounded Sales Growth

10 Years:29.7

5 Years:15.8

3 Years:9.4

TTM:3.5

Compounded Profit Growth

10 Years:35.3

5 Years:14.1

3 Years:6.8

TTM:0.8

Stock Price CAGR

10 Years:N/A

5 Years:N/A

3 Years:N/A

TTM:-2.1

Return on Equity

10 Years:13.5

5 Years:31.6

3 Years:32

last year:48.3

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	413	401	401	401	401
Total Reserves	1,42,475	92,998	73,951	61,152	46,819
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	74,199	1,873	1,992	1,687	1,073
Other Current Liabilities	13,351	7,555	3,861	4,729	2,828
Short Term Borrowings	25,131	1,515	1,150	7,946	1,584
Total Liabilities	2,76,516	1,18,829	96,857	91,084	63,236
Capital Work in Progress	3,061	2,071	4,932	6,699	3,716
Long Term Loans & Advances	2,931	1,640	1,875	1,639	1,581
Currents Investments	16,908	22,581	10,755	8,745	13,062
Short Term Loans and Advances	10,108	10,935	6,567	8,043	2,758
Total Current Assets	69,856	65,655	43,246	44,038	38,796
Total Assets	2,76,516	1,18,829	96,857	91,084	63,236
Adjusted Book Value	346	233	186	154	118

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 46.14, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 25.1%, indicating sustained price appreciation.
The stock carries a low beta of 0.7, suggesting lower volatility than the broader market.
In the last financial year, the company reported an EBITDA of ₹35573 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹122074 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 978938.6

No. of Shares: 440 (Approx)

Performance:-2.1%

P/L: ₹-21061.4

NIFTY Performance: 9.9%

1 day Top Gainers